$GWAV

Greenwave Technology Solutions, Inc. (GWAV): Entry into a Material Definitive Agreement

Greenwave Technology Solutions, Inc. (GWAV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement Private Placement Preferred Stock Purchase Agreement On September 7, 2026, Greenwave Technology Solutions, Inc., a Delaware corporation (the “Company”) entered into a Preferred Stock Purchase Agreement (the “Purchase Agreement

Original reporting
Published Sep 8, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GWAV
Neutral
medium confidence
Mentioned
$GWAV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GWAVNeutralLow
01

Why it matters

The filing provides the first public disclosure of the raise, indicating $3.75 M of new capital and a conversion price of $5.24 per share.

02

Market read

A small‑cap financing event with limited immediate market impact but potential future dilution.

03

What to watch

Potential future conversion of preferred shares could increase share count significantly if the company raises equity later.

Relevance 6/10Novelty 8/10Timing: closing expected Sep 9 2026

Background

Greenwave Technology Solutions filed a Form 8‑K reporting a private placement of Series B convertible preferred stock to five institutional investors.

Company-level read

Ticker impact

$GWAVNeutralMedium confidence
Context

Company filed an 8‑K announcing a private placement of Series B convertible preferred stock raising about $3.75 million.

Expected impact

Minor upside if proceeds improve liquidity, but potential downside from dilution.

Evidence & confidence

Small‑cap raise, limited proceeds, no immediate use beyond working capital; market reaction typically muted.

Market effects

Adds modest financing activity to the niche tech services sector.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global relevance.

Counterpoint

The dilution risk may outweigh the modest capital infusion, prompting a short bias.

Key entities

  • Greenwave Technology Solutions, Inc.

    Issuer of the preferred stock.

  • Series B Convertible Preferred Stock

    Convertible preferred shares with conversion price $5.24.

Related articles

$GWAVHighAI 9/10

Greenwave Announces Receipt of Additional Delinquency Notice from Nasdaq

Greenwave Technology Solutions said Nasdaq issued an additional delinquency notice on May 21, 2026 for its delayed Q1 2026 Form 10-Q filing, citing noncompliance with Nasdaq Listing Rule 5250(c)(1). The company previously received a delinquency notice for its late 2025 Form 10-K. Nasdaq gives until June 22, 2026 to submit a compliance plan; trading remains on Nasdaq under “GWAV.”

$CRWVHighAI 8/10

Why CoreWeave Is Tumbling Hard While the Market Is Soaring

CoreWeave (CRWV) shares fell 3.5% midday, underperforming the S&P 500's 0.9% rise, amid a $3.5B convertible note offering and 35M share ATM program, raising dilution concerns. The company has $72B in liabilities and a $626M Q2 net loss, despite strong demand and revenue growth. Analysts maintain an average $144 price target.

$QBTSHigh

QBTS Stock Rallies As U.S. Backs Quantum Expansion

D-Wave Quantum Inc. (QBTS) stock rose 7.87% on U.S. government backing and positive analyst coverage. The company secured up to $100M in CHIPS Act funding, and BMO Capital initiated coverage with a $35 price target. QBTS reported $24.6M annual revenue, negative margins, and $296.6M in cash. NTT DOCOMO's use of its quantum tech also drove interest.

$SNYLowAI 8/10

Sanofi announces new $925 million flu vaccine facility in Toronto

Sanofi announced a $925 million flu vaccine facility in Toronto, with partial funding from the federal government ($55 million) and the City of Toronto. The project is expected to create 300 jobs and enhance local vaccine supply. Premier Doug Ford emphasized Ontario's investment philosophy and the importance of domestic vaccine production.